News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biovail Corporation (BVF) and MedGenesis Therapeutix Announce Grant from The Michael J. Fox Foundation for the Development of GDNF



6/23/2010 6:59:08 AM

TORONTO, Canada--(BUSINESS WIRE)--Biovail Corporation (NYSE, TSX: BVF) and MedGenesis Therapeutix Inc. today announced that The Michael J. Fox Foundation (MJFF) for Parkinson's Research has awarded a $2.1 million grant to Biovail Laboratories International SRL (BLS) and MedGenesis Therapeutix, Inc. to further their collaboration in the development of glial-cell line derived neurotrophic factor (GDNF). The grant will be made over a 3-year period; with the total amount being subject to the attainment of specific milestones.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES